Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Novo Nordisk A/S (NVO)

121.23   2.44 (2.05%) 11-28 16:00
Open: 120 Pre. Close: 118.79
High: 121.875 Low: 119.54
Volume: 1,848,210 Market Cap: 272,976(M)

Technical analysis

as of: 2022-11-28 4:41:58 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 142.34     One year: 166.25
Support: Support1: 111.56    Support2: 105.19
Resistance: Resistance1: 121.87    Resistance2: 142.34
Pivot: 115.03
Moving Average: MA(5): 117.33     MA(20): 114.01
MA(100): 108.02     MA(250): 107.7
MACD: MACD(12,26): 2.8     Signal(9): 2.3
Stochastic oscillator: %K(14,3): 96.9     %D(3): 91
RSI: RSI(14): 71.7
52-week: High: 122.16  Low: 91.51
Average Vol(K): 3-Month: 1,297 (K)  10-Days: 1,062 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ NVO ] has closed above the upper band by 13.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 16.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 121.88 - 122.31 122.31 - 122.7
Low: 118.31 - 118.86 118.86 - 119.36
Close: 120.36 - 121.12 121.12 - 121.83

Company Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Headline News

Mon, 28 Nov 2022
Is Novo Nordisk A/S (NVO) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Wed, 23 Nov 2022
Novo Nordisk A/S (NVO) is up 1.25% Wednesday In Premarket Trading - InvestorsObserver

Tue, 22 Nov 2022
Novo Resources (TSX:NVO) Provides Exploration Update From Malmsbury and Queens Projects in Victoria, Australia - MiningFeeds.com

Wed, 16 Nov 2022
BAYRY vs. NVO: Which Stock Is the Better Value Option? - Nasdaq

Mon, 14 Nov 2022
What is Wall Street's Target Price for Novo Nordisk A/S (NVO) Stock Monday? - InvestorsObserver

Mon, 07 Nov 2022
Is Novo Nordisk A/S (NVO) a Bad Choice in Biotechnology Monday? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 2,280 (M)
Shares Float 1,620 (M)
% Held by Insiders 0 (%)
% Held by Institutions 8.6 (%)
Shares Short 3,220 (K)
Shares Short P.Month 3,120 (K)

Stock Financials

EPS 2.92
EPS Est Next Qtl 0.52
EPS Est This Year 2.42
EPS Est Next Year 2.58
Book Value (p.s.) 27.37
Profit Margin (%) 32.1
Operating Margin (%) 42.6
Return on Assets (ttm) 22.2
Return on Equity (ttm) 72.1
Qtrly Rev. Growth 24.8
Gross Profit (p.s.) 51.37
Sales Per Share 68.96
EBITDA (p.s.) 31.58
Qtrly Earnings Growth 11.3
Operating Cash Flow 66,040 (M)
Levered Free Cash Flow 55,340 (M)

Stock Valuations

PE Ratio 41.51
PEG Ratio 125.2
Price to Book value 4.42
Price to Sales 1.75
Price to Cash Flow 4.18

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2021-08-24
Ex-Dividend Date 2021-08-15
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.